Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ostenil Tendon is a branded, injectable viscoelastic solution of highly purified, biofermented sodium hyaluronate at 2% (40 mg/2 ml) combined with mannitol, developed for peritendinous or intrasheath administration to treat pain and restricted mobility associated with tendinopathies and other tendon disorders.[1][9][11][14][13] As a high–molecular weight hyaluronic acid device, it acts locally to restore lubrication and viscoelasticity within the tendon sheath, enhancing tendon gliding, reducing adhesions, and limiting diffusion of inflammatory cells and mediators, while mannitol scavenges free radicals to stabilize the hyaluronate chains and prolong their local persistence.[1][11][14] The product is supplied as a single-use, pre-filled 2 ml syringe and is typically given as two injections at weekly intervals around or into the tendon sheath, and is classified and marketed as a medical device rather than a systemic pharmaceutical drug.[1][9][11][15]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ostenil Tendon.